Voyageur PharmaceuticalsVYYRF 14 EBIT per Share is $-0.01 as of Feb. 2026. GuruFocus rates VYYRF with a GF Score™ of 14/100. The stock has 5 warning signs investors should review. Among 809 Drug Manufacturers companies, Voyageur Pharmaceuticals ranks worse than 76.02% on this metric.
Voyageur Pharmaceuticals's EBIT per Share for the
three
months ended in Feb. 2026 was $-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 was $-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was -9.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 0.70% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -10.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Voyageur Pharmaceuticals's EBIT per Share or its related term are showing as below:
VYYRF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -162.1 Med: 10.6 Max: 80.6
Current: -9.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Voyageur Pharmaceuticals was 80.60% per year. The lowest was -162.10% per year. And the median was 10.60% per year.
VYYRF's 3-Year EBIT Growth Rate is ranked worse than 76.02% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.6
vs VYYRF: -9.50
Voyageur Pharmaceuticals (OTCPK:VYYRF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Voyageur Pharmaceuticals EBIT per Share Related Terms
Voyageur Pharmaceuticals EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyageur Pharmaceuticals (VYYRF) has a EBIT per Share of $-0.01 as of Feb. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Voyageur Pharmaceuticals and its competitors. According to the industry distribution chart, Voyageur Pharmaceuticals ranks #615 out of 809 companies in the Drug Manufacturers industry, placing it in the top 76%.
Is Voyageur Pharmaceuticals' EBIT per Share too high?
Voyageur Pharmaceuticals' current EBIT per Share is $-0.01. Based on the distribution chart, Voyageur Pharmaceuticals ranks #615 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Voyageur Pharmaceuticals has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Voyageur Pharmaceuticals ranks #615 out of 809 companies for EBIT per Share. This places Voyageur Pharmaceuticals in the lower half of its industry. The industry median EBIT per Share is 7.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Voyageur Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyageur Pharmaceuticals's current EBIT per Share is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current EBIT per Share of $-0.01. The current EBIT per Share is $-0.01. Voyageur Pharmaceuticals' overall GF Score™ is 14/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current EBIT per Share is $-0.01 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
14GF Score
Get the complete analysis for VYYRF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VYYRF has been successfully added to your 
